公开(公告)号：WO2023079137A1

公开(公告)日：2023-05-11

申请号：PCT/EP2022/080965

申请日：2022-11-07

申请人： KATHOLIEKE UNIVERSITEIT LEUVEN ,  VIB VZW ,  UNIVERSITEIT GENT

发明人： GEUKENS, Nick ,  DECLERCK, Paul ,  IMBRECHTS, Maya ,  AMPOFO, Louanne ,  MAES, Wim ,  NEYTS, Johan ,  ABDELNABI, Rana ,  EECKHAUT, Hannah ,  CALLEWAERT, Nico ,  FIJALKOWSKA, Daria

IPC分类号： C07K16/10 ,  A61K39/395 ,  A61P31/14 ,  C12N15/13 ,  A61K2039/505 ,  A61K2039/53 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to antibodies or antigen binding fragments thereof, specifically binding to the trimeric spike protein of Wuhan Covid-SARS-2 and specifically binding to the RBD domain of all of Wuhan, alpha, beta, gamma, delta and omicron variant of Covid-SARS-2 spike protein, characterized in that said antibody or antigen binding fragment thereof has an IC50 in a SARS-CoV-2 pseudovirus infection lower than 1 nm in a SARS-CoV-2 pseudovirus infection, and in that said antibody or antigen binding fragment thereof has an affinity for RBD domain Wuhan Covid-SARS-2 spike protein with a KD of less than 500 pM, and in that said antibody or antigen binding fragment thereof has an affinity for trimeric spike protein of Wuhan Covid-SARS-2 with a KD of less than 300 pM.

公开(公告)号：WO2023077090A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078912

申请日：2022-10-28

申请人： BRISTOL-MYERS SQUIBB COMPANY

发明人： SRIVASTAVA, Shivani ,  AGRAWAL, Shrutidevi Kunjbiharilal ,  GELB, Arnold Bruce ,  CHEONG, Alicia Mun Yen

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61P35/02 ,  A61K39/395 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55 ,  C07K16/2803 ,  C07K16/2818 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

摘要： The disclosure provides a method of treating a human subject afflicted with a hematological cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor). In some aspects, the subject is greater than or equal to about 12 years old and has a weight of greater than or equal to about 40 kg, including subjects less than or equal to about 30 years old or less than about 18 years old. In some aspects, the subject has a weight of less than about 40 kg and/or is less than about 12 years old.

公开(公告)号：WO2023067031A2

公开(公告)日：2023-04-27

申请号：PCT/EP2022/079144

申请日：2022-10-19

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： BACCONI, Marta ,  BARDELLI, Monia ,  BRUNELLI, Brunella ,  DEWAR, Vincent ,  FRIGIMELICA, Elisabetta ,  MALZONE, Carmine ,  PANSEGRAU, Werner ,  VEGGI, Daniele

IPC分类号： G01N33/537 ,  C07K16/12 ,  G01N33/569 ,  G01N33/577 ,  G01N33/58 ,  C07K16/1217 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56911 ,  G01N33/585

摘要： This invention provides a multiplex binding assay for analysing a meningococcal vaccine and assessing in vitro relative potency of the same (IVRP). The invention also provides monoclonal antibodies which bind to meningococcal proteins within the vaccine, and in particular monoclonal antibodies which are bactericidal for meningococcus and/or which recognise conformational epitopes within the meningococcal proteins.

公开(公告)号：WO2023036986A2

公开(公告)日：2023-03-16

申请号：PCT/EP2022/075300

申请日：2022-09-12

申请人： HARBOUR ANTIBODIES BV ,  UNIVERSITEIT UTRECHT HOLDING BV ,  ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM

发明人： GROSVELD, Franklin Gerardus ,  BOSCH, Berend Jan ,  HAAGMANS, Bartholomeus Leonard

IPC分类号： C07K16/10 ,  A61K39/395 ,  A61P31/14 ,  C12N15/13 ,  C07K2317/31 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to heavy chain-only antibodies that recognize SARS-CoV-2 spike protein (SARS2-S). In some embodiments, the antibodies bind to SARS2-S with high affinity and/or inhibit SARS-Cov-2 infection of human cells. In some embodiments, the antibodies provide a means of preventing, treating or ameliorating SARS2 infection. In some embodiments, the antibodies are used in diagnostic assays (e.g. serodiagnostic assays for SARS2).

公开(公告)号：WO2023012343A1

公开(公告)日：2023-02-09

申请号：PCT/EP2022/072123

申请日：2022-08-05

申请人： INSTITUT DU CANCER DE MONTPELLIER ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE DE MONTPELLIER

发明人： LINARES, Laetitia ,  FIRMIN, Nelly ,  MANTEAUX, Gabrielle

IPC分类号： A61P35/00 ,  C07K16/24 ,  C07K16/28 ,  A61K39/395 ,  G01N33/53 ,  G01N33/574 ,  A61K2039/505 ,  A61K2039/55 ,  C07K16/248 ,  C07K16/2803 ,  C07K16/2866 ,  C07K2317/14 ,  C07K2317/76 ,  G01N33/57496 ,  G01N33/6869

摘要： The present disclosure relates to an Interleukin-6 (IL-6) signaling inhibitor selected from an IL-6 inhibitor, an IL-6 receptor inhibitor, an IL-6/IL-6 receptor complex inhibitor, a gp130 inhibitor and a STAT3 inhibitor or a pharmaceutical composition comprising such an IL-6 signaling inhibitor, for use in a method for treating and/or preventing cancer in a subject in need thereof, wherein the subject has been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin. The inventors have observed that cancers exhibiting recruitment of MDM2 to chromatin have been shown to secrete IL-6 that in turn acts on myoblast cells to activate serine synthesis. Following these surprising and unexpected observations, the inventors set up methods of treatment that are able to induce cancer cells death in subjects that have been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin.

公开(公告)号：WO2023012314A1

公开(公告)日：2023-02-09

申请号：PCT/EP2022/072030

申请日：2022-08-04

申请人： LIFEARC ,  MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.

发明人： WORZFELD, Thomas ,  OFFERMANNS, Stefan ,  MATTHEWS, David ,  OLEKSY, Arkadiusz ,  TROKTER, Martina ,  PATEL, Seema ,  KAUR NIJJAR, Sharandip

IPC分类号： A61P19/10 ,  A61P25/00 ,  C07K16/28 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/76

摘要： The invention relates to antibodies and antigen binding fragments thereof that specifically bind to Plexin-B1 and their therapeutic uses. The antibodies are useful in treating osteoporosis, multiple sclerosis, a neoplastic disease or a neurodegenerative disease in a subject.

公开(公告)号：WO2023010076A1

公开(公告)日：2023-02-02

申请号：PCT/US2022/074255

申请日：2022-07-28

申请人： ALECTOR LLC

发明人： PINCETIC, Andrew ,  ROSENTHAL, Arnon

IPC分类号： A61P21/00 ,  A61P25/28 ,  A61P29/00 ,  A61P37/06 ,  C07K16/28 ,  G01N33/50 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/71 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2800/24 ,  G01N33/6896

摘要： The present disclosure provides antibodies and antibody fragments that bind to human SIRPA. In some embodiments, the antibodies are SIRPA agonists. The antibodies and antibody fragments disclosed herein may be used for the treatment and/or diagnosis of diseases, disorders, and conditions associated with reduced SIRPA activity.

公开(公告)号：WO2023010065A2

公开(公告)日：2023-02-02

申请号：PCT/US2022/074238

申请日：2022-07-28

申请人： CEPHALON LLC

发明人： DOYLE, Anthony Gerard ,  CLARKE, Adam ,  BUTT, Danyal ,  LAINE, David ,  MACRAE, Hugh ,  VO, Jenny ,  ROZENFELD, Julia ,  SURADE, Sachin

IPC分类号： C07K16/26 ,  A61K38/17 ,  A61K39/395 ,  A61P25/06 ,  A61K2039/505 ,  A61K39/00 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The present disclosure generally relates to anti-PACAP antibodies, pharmaceutical compositions comprising such antibodies, and methods of producing and using such antibodies.

公开(公告)号：WO2023004431A2

公开(公告)日：2023-01-26

申请号：PCT/US2022/074075

申请日：2022-07-22

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： HO, David, D. ,  HUANG, Yaoxing ,  LIU, Lihong ,  NAIR, Manoj, S. ,  YU, Jian ,  IKETANI, Sho

IPC分类号： A61K39/42 ,  A61P31/14 ,  C07K16/10 ,  C12N15/13 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92

摘要： The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.

公开(公告)号：WO2023287573A2

公开(公告)日：2023-01-19

申请号：PCT/US2022/035376

申请日：2022-06-28

申请人： MABWELL THERAPEUTICS INC.

发明人： CHEN, Buxin ,  HUANG, Lei ,  DU, Xin

IPC分类号： A61P37/06 ,  C07K16/18 ,  C07K16/40 ,  A61K39/00 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： Antibodies and antigen-binding fragments thereof that bind C1s and inhibit C1s activity and modulate the activity of at least one component in the classical pathway (CP) of complement activation, and methods for treating complement-mediated disorders using anti-C1s antibodies and fragments, are provided.